Results 31 to 40 of about 23,087 (229)

Clinical utility of denosumab for treatment of bone loss in men and women [PDF]

, 2011
Robert A Adler, Ranjodh S GillEndocrinology and Metabolism, McGuire Veterans Affairs Medical Center, Richmond, VA, USAAbstract: While most older patients with osteoporosis are treated with antiresorptive bisphosphonates such as alendronate, risedronate ...
Adler R, Gill RS, null Gill, Robert Adler   +3 more
core   +1 more source

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

, 2009
Androgen-deprivation therapy is well-established for treating prostate cancer but is associated with bone loss and an increased risk of fracture. We investigated the effects of denosumab, a fully human monoclonal antibody against receptor activator of ...
Szwedowski, M., Smith, MR, Kupic, A, Tammela, T.L., Saad, F, Denosumab, HALT Prostate Cancer Study Group, Goessl, C, Feldman, R, Tammela, TL, Hernández Toriz, N., Ke, C, Szwedowski, M, Goessl, C., Leder, B.Z., Heracek, J, Kupic, A., Ke, C., Egerdie, B., Heracek, J., Leder, BZ, Hernández Toriz, N, Egerdie, B, Saad, F., Feldman, R., Smith, M.R.   +24 more
core   +1 more source

Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases

Bone Reports, 2022
Denosumab is a commonly used antiresorptive treatment in patients with osteoporosis or solid tumours with bone metastases. Upon denosumab discontinuation, a rebound phenomenon can occur that results in an increased (vertebral) fracture risk.
Jolan Dupont, Wesley Appermans, Marian Dejaeger, Isabelle Wauters, Michaël R. Laurent, Evelien Gielen   +5 more
doaj   +1 more source

Rebound hypercalcemia after denosumab cessation during follow-up after surgical treatment for parathyroid carcinoma: case report and literature review [PDF]

Archives of Endocrinology and Metabolism
SUMMARY Denosumab is a potent antiresorptive medication, commonly used in the treatment of osteoporosis, as well as in a variety of other diseases.
Lisa Schmitt, Verena Theiler-Schwetz, Patrick Sadoghi, Christian Trummer, Stefan Pilz   +4 more
doaj   +1 more source

Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis. [PDF]

, 2022
Osteonecrosis of the jaw (ONJ) is a rare but serious adverse event associated with antiresorptive treatment. There is little evidence regarding the incidence of ONJ among patients with osteoporosis who are treated with denosumab versus bisphosphonates ...
Ziswiler, Hans-Rudolf, Gahl, Brigitta, Judith Everts‐Graber, Benoît Schaller, John‐Patrik Burkard, Burkhard, John Patrik Matthias, Stephan Reichenbach, Brigitta Gahl, HansJörg Häuselmann, Hans‐Rudolf Ziswiler, Daniel Lehmann, Reichenbach, Stephan, Schaller, Benoît, Ueli Studer, Lehmann, Daniel, Thomas Lehmann, Lehmann, Thomas, Studer, Ueli, Everts-Graber, Judith, Häuselmann, HansJörg   +19 more
core   +3 more sources

Plain language summary of publication to understand the ROSALIA study: a new biosimilar denosumab for bone health

Therapeutic Advances in Musculoskeletal Disease
Summary What is this summary about? This plain language summary describes the results of a clinical study, ROSALIA , which was published in the Journal of Bone and Mineral Research in 2024. The ROSALIA study looked at whether biosimilar denosumab has the
Richard Eastell, Sławomir Jeka, Maryam Lustberg, Colin Edgerton, Paweł Żuchowski, Barbara Vogg   +5 more
doaj   +1 more source

Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study. [PDF]

, 2023
UNLABELLED This registry-based study of 3068 patients with osteoporosis compared the anti-fracture effectiveness of denosumab versus bisphosphonates.
Ziswiler, Hans-Rudolf, Gahl, Brigitta, Hans-Rudolf Ziswiler, Harald Bonel, Stephan Reichenbach, Brigitta Gahl, HansJörg Häuselmann, Daniel Lehmann, Judith Everts-Graber, Bonel, Harald, Reichenbach, Stephan, Ueli Studer, Lehmann, Daniel, Thomas Lehmann, Lehmann, Thomas, Studer, Ueli, Everts-Graber, Judith, Häuselmann, HansJörg   +17 more
core   +2 more sources

2D copper nanozyme patches facilitate bone regeneration via interfacial modulation of osteoclast‐osteoblast dynamics

BMEMat, EarlyView.
This study develops a nano‐enzyme patch (ezPatch) targeting bone interfaces. Utilizing ligand‐to‐metal charge transfer (LMCT) catalysis and bone‐targeting ligands on copper nanosheets, ezPatch simultaneously scavenges reactive oxygen species (ROS) and generates oxygen in situ at bone‐losing sites.
Yi Chen, Haoyue Hu, Danyang Wang, Ying Wang, Zhibang Li, Xiaoyi Liu, Yandi Zhang, Junkun Feng, Weiwei Zhao, Kai Li, Qi‐Zhi Zhong, Shaohua Ge, Jianhua Li   +12 more
wiley   +1 more source

Pregnancy‐ and lactation‐associated osteoporosis: A position statement of the IAPM, IOF, ECTS, ESCEO, IMS, and EMAS

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Pregnancy‐ and lactation‐associated osteoporosis (PLO) is a syndrome characterized by fragility fractures (most commonly vertebral, often multiple) occurring in late pregnancy or the early postpartum period. This position statement summarizes the current knowledge of PLO, and the recommended procedure for assessment, diagnosis and treatment ...
Peyman Hadji, Apostolos Athanasiadis, Maria‐Luisa Brandi, Marlene Chakhtoura, Manju Chandran, Frank Chervenak, Amos Grünebaum, Irene Lambrinoudaki, Willem F. Lems, Apostolos M. Mamopoulos, Eugene McCloskey, Rossella E. Nappi, Jessica Pepe, Jean‐Yves Reginster, René Rizzoli, Petra Stute, Şansın Tuzun, Amanda J. Vincent, Maria Belen Zanchetta, M. Carola Zillikens, Ioannis Kyvernitakis   +20 more
wiley   +1 more source

Hormone therapy (HT) in women with premature ovarian insufficiency or early menopause: Time to think of a new paradigm for healthy aging. A joint FIGO and IMS position paper

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Premature ovarian insufficiency (POI) and early menopause (EM) affect millions of women worldwide. Compared with normal menopause, they confer a longer duration of estrogen deficiency and are associated not only with a shorter lifespan, but with a reduced healthspan, owing to an increased risk of cardiovascular, skeletal, cognitive and ...
Chiara Benedetto, Suvarna S. Khadilkar, Rossella E. Nappi, Andrea R. Genazzani, Federica Frezet, Laura Cucinella, Hema Divakar, Panagiotis Anagnostis, Nick Panay   +8 more
wiley   +1 more source